First and second wave of SARS-CoV2 in Italian Cystic Fibrosis patients: Data from Italian Cystic Fibrosis Registry

Padoan, Rita; Carnovale, Vincenzo; Salvatore, Donatello; Quattrucci, Serena; Taruscio, Domenica; Floridia, Giovanna; Amato, Arnaldo; Ferrari, Gianluca; Campagna, Giuseppe; Salvatore, Marco

doi:10.1016/j.jcf.2021.01.008

Cited by 5 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of COVID-19 by PCR in our cohort of pwCF was 1.6%, which is lower than the NY general population rate (2.69%) but higher than in many European countries during the first wave of the pandemic [6] , [7] , [8] , [9] , [10] . It is not surprising that our reported prevalence in pwCF was higher than other regions internationally as NY was the epicenter of the COVID-19 pandemic's first wave in the U.S.…”

Section: Discussioncontrasting

confidence: 75%

“…The Abbot Architect CMIA reported 1 false positive in a sample of 1,020 specimens and the diagnostic accuracy of the Roche Elecsys ECLIA is comparable [18] , [19] . Consistent with prior literature in pwCF, the prevalence of COVID-19 by PCR was calculated based on the number patients in the overall cohort [ 6 , [8] , [9] , [10] ], as testing was often prompted by symptoms. The prevalence of COVID-19 by IgG antibody testing was calculated differently, similar to prior studies in pwCF, based on the number of patients tested [14] , [15] , [16] , as testing was performed for screening purposes.…”

Section: Methodsmentioning

confidence: 99%

“…Registry-based international studies revealed a lower-than-expected incidence of COVID-19 in pwCF from March to June, 2020 compared to the general population [5][6][7][8][9][10]. First wave COVID-19 incidence in French and Italian CF centers was 0.41% and 0.40%, respectively, and lower than the general population [8][9]. The European CF Society Patient Registry reported an incidence of 0.27%, similar to the general population, however by age groups, incidence was higher in pwCF [10].…”

Section: Introductionmentioning

confidence: 93%

“…In contrast to the H1N1 pandemic, the COVID-19 pandemic resulted in extensive global lockdown and implementation of universal masking and contact precautions. Registry-based international studies revealed a lower-than-expected incidence of COVID-19 in pwCF from March to June, 2020 compared to the general population [5][6][7][8][9][10]. First wave COVID-19 incidence in French and Italian CF centers was 0.41% and 0.40%, respectively, and lower than the general population [8][9].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

Simonson

Esposito

Frantzen

et al. 2022

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 75%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

Simonson

Esposito

Frantzen

et al. 2022

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

“…2 The fatality rate and severity of the coronavirus disease 2019 (COVID-19) is highly affected by age, ethnic group or underlying medical conditions 3 cystic fibrosis (CF), a progressive genetic disorder that affects the lungs, pancreas, and other organs is one of the most common chronic lung diseases in children and young adults. 4 In this context, initial expectations regarding COVID-19 outcomes and mortality rates for patients with CF have been surpassed, 5 as reported experiences, in different countries, have shown better outcomes than anticipated [6][7][8][9][10][11][12][13][14] In CF patients, viral respiratory tract infections are usually more severe than in the general population, with an increased risk of complications, an associated decrease in lung function and a higher mortality. 15 However, CF patients have not exhibited higher rates of SARS-CoV-2 infection compared to the general population, with no apparent impact on the severity of their CF.…”

mentioning

confidence: 99%

SARS‐CoV‐2 infection in children with cystic fibrosis: A cross‐sectional multicenter study in Spain. New waves, new knowledge

Mondejar‐Lopez,

Moreno‐Galarraga,

de Manuel‐Gomez

et al. 2023

Pediatric Pulmonology

View full text Add to dashboard Cite

IntroductionThe association between viral infections and pulmonary exacerbations in children with cystic fibrosis (cwCF) is well established. However, the question of whether cwCF are at a higher risk of COVID‐19 or its adverse consequences remains controversial.MethodsWe conducted an observational, multicenter, cross‐sectional study of cwCF infected by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) between March 2020 and June 2022, (first to sixth COVID‐19 pandemic waves) in Spain. The study aimed to describe patients' basal characteristics, SARS‐CoV‐2 clinical manifestations and outcomes, and whether there were differences across the pandemic waves.ResultsDuring study time, 351 SARS‐CoV2 infections were reported among 341 cwCF. Median age was 8.5 years (range 0–17) and 51% were female. Cases were unevenly distributed across the pandemic, with most cases (82%) clustered between November 2021 and June 2022 (sixth wave, also known as Omicron Wave due to the higher prevalence of this strain in that period in Spain). Most cwCF were asymptomatic (24.8%) or presented with mild Covid‐19 symptoms (72.9%). Among symptomatic, most prevalent symptoms were fever (62%) and increased cough (53%). Infection occurring along the sixth wave was the only independent risk factor for being symptomatic. Just eight cwCF needed hospital admission. No multisystem inflammatory syndrome, persisting symptoms, long‐term sequelae, or deaths were reported.ConclusionsSpanish current data indicate that cwCF do not experience higher risks of SARS‐CoV‐2 infection nor worse health outcomes or sequelae. Changes in patients' basal characteristics, clinical courses, and outcomes were detected across waves. While the pandemic continues, a worldwide monitoring of COVID‐19 in pediatric CF patients is needed.

show abstract

The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review

Vitiello,

Sabbatucci,

Silenzi

et al. 2023

Respir Res

View full text Add to dashboard Cite

Several risk factors for Coronavirus-2019 (COVID-19) disease have been highlighted in clinical evidence. Among the various risk factors are advanced age, metabolic illness such as diabetes, heart disease, and diseases of the respiratory system. Cystic Fibrosis (CF) is a rare disease with autosomal recessive transmission, characterised by a lack of synthesis of the CFTR channel protein, and multi-organ clinical symptoms mainly affecting the respiratory tract with recurrent pulmonary exacerbations. In view of the pathophysiological mechanisms, CF disease should be in theory considered a risk factor for SARS-CoV2 or severe COVID-19. However, recent clinical evidence seems to point in the opposite direction, suggesting that CF could be a protective factor against severe COVID-19. Possibly, the lack of presence or function of the CFTR channel protein could be linked to the expression of the membrane glycoprotein ACE-2, a key enzyme for the endocellular penetration of SARS-CoV-2 and related to the pathophysiology of COVID-19 disease. Furthermore, CFTR channel modulating agents could indirectly influence the expression of ACE-2, playing an important role in restoring the proper functioning of mucociliary clearance and the pulmonary microbiome in the host response to SARS-CoV-2 infection. In this review, the authors attempt to shed light on these important associations of issues that are not yet fully elucidated.

show abstract

First and second wave of SARS-CoV2 in Italian Cystic Fibrosis patients: Data from Italian Cystic Fibrosis Registry

Cited by 5 publications

References 4 publications

The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

The clinical impact of the Covid-19 pandemic first wave on patients with cystic fibrosis in New York

SARS‐CoV‐2 infection in children with cystic fibrosis: A cross‐sectional multicenter study in Spain. New waves, new knowledge

The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review

Contact Info

Product

Resources

About